Protein Degradation & Targeting Undruggables 2022

Application of Emerging Degradative Technologies and Small Molecule Transcription Modulators to Establish Clinically and Commercially Viable Therapeutics

Download Agenda
8-9 MARCH in BOSTON, USA | 7 & 10 MARCH ONLINE
7-10 March, 2022

“This event gathered the world leaders in the protein degradation field. I thoroughly enjoyed the opportunity to get up to date on the latest approaches used by both pharma companies and academics. The set up also allowed a great opportunity to network. I will definitely be back!”

- NIH

Why Attend

The Protein Degradation and Targeting Undruggables Summit is the only industry-led forum giving you in-person insight into the full range of novel therapeutic approaches targeting the undruggable and expanding the scope of therapeutically reachable targets. Entering its 3rd edition, this event will take place over two face-to-face days in Boston (8-9 March 2022) and two digital days (7 & 10 March 2022) and will allow you to have in-depth conversations on the latest in vitro and in vivo data driving forward the translation of undrugged research into clinically and commercially viable products.

Featuring characteristics of lacking defined ligand-binding pockets, non-catalytic protein–protein interaction functional modes and less-investigated 3D structures, undruggable targets have needed unconventional drug discovery approaches, such as proximity-dependent transcription factor and molecular glue degradation, to generate novel therapeutic entities. This open forum is a unique opportunity to gather with leading biopharma, expert academic centers and innovative service providers to discuss and share R&D strategies for progressing novel modalities at the frontier of drug discovery.

For this year’s edition of the conference there will be enhanced focus on:

  • Enabling selectivity and specificity of targeting transcription factors
  • Emerging modalities outside PROTACs 
  • Dedicated discussion on challenges including lead optimization, phenotypic assays and identifying new E3 ligases

Ensure your R&D team takes full advantage of the informative industry presentations, interactive panel discussions and returns to create broadly applicable drug platforms capable of creating new degrader molecules against additional high value targets and producing commercially robust product pipelines. Do not get left behind in this dynamic, fast-moving field and secure your place today at the most up-to-date and informative congress in the field of undrugged.

2022 SPEAKERS

 

Matthew Disney

Professor
Scripps Reasearch Institute

Matthew Disney

Professor
Scripps Reasearch Institute

Matthew Disney

Professor
Scripps Reasearch Institute
 

Nicolas Thomä

Senior Group Leader
Friedrich Miescher Institute for Biomedical Research

My laboratory has set out to combine structural biology, cell biology and complex biochemical in vitro reconstitutions to address the molecular workings of these chromatin-bound complex assemblies. Our focus is on machines that detect and repair mutations in the DNA, and those that make possible the accurate passage of epigenetic information to the daughter generation.

Nicolas Thomä

Senior Group Leader
Friedrich Miescher Institute for Biomedical Research

Nicolas Thomä

Senior Group Leader
Friedrich Miescher Institute for Biomedical Research

My laboratory has set out to combine structural biology, cell biology and complex biochemical in vitro reconstitutions to address the molecular workings of these chromatin-bound complex assemblies. Our focus is on machines that detect and repair mutations in the DNA, and those that make possible the accurate passage of epigenetic information to the daughter generation.

 

Kevin Foley

Co-founder & Chief Scientific Officer
Ranok Therapeutics Co. Ltd

Kevin Foley

Co-founder & Chief Scientific Officer
Ranok Therapeutics Co. Ltd

Kevin Foley

Co-founder & Chief Scientific Officer
Ranok Therapeutics Co. Ltd
 

Adam Gilbert

Executive Director, Head of Design and Synthesis Sciences
Pfizer

My group supports several important medchem platforms for Pfizer: protein degradation, DNA-encoded library chemistry, large and small-scale compound purification and phenotypic screening deconvolution.  Scientists in my group specialize in design and synthetic medicinal chemistry, computational chemistry, purification science as well as molecular property analysis.

Adam Gilbert

Executive Director, Head of Design and Synthesis Sciences
Pfizer

Adam Gilbert

Executive Director, Head of Design and Synthesis Sciences
Pfizer

My group supports several important medchem platforms for Pfizer: protein degradation, DNA-encoded library chemistry, large and small-scale compound purification and phenotypic screening deconvolution.  Scientists in my group specialize in design and synthetic medicinal chemistry, computational chemistry, purification science as well as molecular property analysis.

 

John Castle

CDS
Monte Rosa Therapeutics

John Castle

CDS
Monte Rosa Therapeutics

John Castle

CDS
Monte Rosa Therapeutics
 

Dan Nomura

Professor
UC Berkely

Dan Nomura

Professor
UC Berkely

Dan Nomura

Professor
UC Berkely
 

Eric Fischer

Associate Professor
Dana-Farber Cancer Institute

Eric Fischer, Ph.D. is Assistant Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and a Principal Investigator in the Department of Cancer Biology at Dana-Farber Cancer Institute. His research focuses on understanding the complex mechanisms that underlie function and regulation of multi-component ubiquitin ligases and their role in disease. His work further focuses on new therapeutic approaches such as targeted protein degradation.

Eric Fischer

Associate Professor
Dana-Farber Cancer Institute

Eric Fischer

Associate Professor
Dana-Farber Cancer Institute

Eric Fischer, Ph.D. is Assistant Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and a Principal Investigator in the Department of Cancer Biology at Dana-Farber Cancer Institute. His research focuses on understanding the complex mechanisms that underlie function and regulation of multi-component ubiquitin ligases and their role in disease. His work further focuses on new therapeutic approaches such as targeted protein degradation. He co-directs the DFCI Center for Protein Degradation and has been recognized for his pioneering work on the structure of cereblon and the mechanism of action of thalidomide.

 

Charles Lin

Vice President of Biology
Kronos Bio, Inc.

Charles Lin

Vice President of Biology
Kronos Bio, Inc.

Charles Lin

Vice President of Biology
Kronos Bio, Inc.
 

Hyunsun Jo

CEO
Pin Therapeutics

Hyunsun Jo

CEO
Pin Therapeutics

Hyunsun Jo

CEO
Pin Therapeutics
 

Jason Hipp

Chair, Division of Computational Pathology & AI, Laboratory Medicine & Pathology
Mayo Clinic

Jason Hipp

Chair, Division of Computational Pathology & AI, Laboratory Medicine & Pathology
Mayo Clinic

Jason Hipp

Chair, Division of Computational Pathology & AI, Laboratory Medicine & Pathology
Mayo Clinic
 

Matthew Calabrese

Senior Director and head of Structural and Molecular Science
Pfizer

Matthew Calabrese

Senior Director and head of Structural and Molecular Science
Pfizer

Matthew Calabrese

Senior Director and head of Structural and Molecular Science
Pfizer
 

Fiona Pachl

Senior Scientist
AstraZenca

Fiona Pachl

Senior Scientist
AstraZenca

Fiona Pachl

Senior Scientist
AstraZenca
 

Zoran Rankovic

Director, CBT Chemistry Centers
St Jude's

Zoran Rankovic

Director, CBT Chemistry Centers
St Jude's

Zoran Rankovic

Director, CBT Chemistry Centers
St Jude's
 

Dirksen Bussiere

Senior Director, Molecular Pharmacology
Eli Lilly

Dirksen Bussiere

Senior Director, Molecular Pharmacology
Eli Lilly

Dirksen Bussiere

Senior Director, Molecular Pharmacology
Eli Lilly
 

Matthias Brand

Founder
Proxygen

Matthias Brand

Founder
Proxygen

Matthias Brand

Founder
Proxygen
 

Scott Hughes

Founder & Director of Exploratory Biology
Amphista Therapeutics

Scott Hughes

Founder & Director of Exploratory Biology
Amphista Therapeutics

Scott Hughes

Founder & Director of Exploratory Biology
Amphista Therapeutics
 

Matthew Bogyo

Group Leader and Professor
Stanford University School of Medicine

Matthew Bogyo

Group Leader and Professor
Stanford University School of Medicine

Matthew Bogyo

Group Leader and Professor
Stanford University School of Medicine
 

Seth Morgalis

Associate Professor
The Johns Hopkins University School of Medicine

Seth Morgalis

Associate Professor
The Johns Hopkins University School of Medicine

Seth Morgalis

Associate Professor
The Johns Hopkins University School of Medicine
 

Shaomeng Wang

Professor of Internal Medicine, Pharmacology and Medicinal Chemistry
University of Michigan

I have been working on the discovery and development of novel small-molecules therapeutics for more than 20 years. One area of my research has been focused on targeting protein-protein interactions which regulate apoptosis, including the PPIs between the anti-death Bcl-2 and pro-death Bcl-2 members, the MDM2-p53 PPI, and the PPI of IAP proteins with Smac. My research in targeting apoptosis has resulted in the discovery and advancement of 8 compounds into Phase I/II clinical development targeting Bcl-2/Bcl-xL, MDM2 and IAP proteins.

Shaomeng Wang

Professor of Internal Medicine, Pharmacology and Medicinal Chemistry
University of Michigan

Shaomeng Wang

Professor of Internal Medicine, Pharmacology and Medicinal Chemistry
University of Michigan

I have been working on the discovery and development of novel small-molecules therapeutics for more than 20 years. One area of my research has been focused on targeting protein-protein interactions which regulate apoptosis, including the PPIs between the anti-death Bcl-2 and pro-death Bcl-2 members, the MDM2-p53 PPI, and the PPI of IAP proteins with Smac. My research in targeting apoptosis has resulted in the discovery and advancement of 8 compounds into Phase I/II clinical development targeting Bcl-2/Bcl-xL, MDM2 and IAP proteins. In more recent years, I have expanded my research program to target a number of PPIs, which regulate epigenetics, including histone readers, writers and erasers, and have advanced several classes of compounds into advanced preclinical development. To accomplish our goals of discovering highly optimized compounds suitable for clinical development and rapidly advancing them into clinical development, I have established extensive collaborations with basic scientists, translational scientists and clinical investigators at UMCCC and in other institutions. I have co-founded five UM start-up companies to help us to bring our drugs into clinical development and marketplace. I have published 300+ peer-reviewed papers and an inventor of 50+ issued US patents and hundreds of international patents. I was elected as Fellow of the National Academy of Inventors in 2014 and as Fellow of the American Association for the Advancement of Science (AAAS) in 2019, was induced into Hall of Fame of the Division of Medicinal Chemistry of American Chemical Society in 2020. I was the 2014 University of Michigan Distinguished Innovator.

 

Ryan Potts

Executive Director and Head of Induced Proximity Platform
Amgen

Ryan Potts, Ph.D. obtained his B.S. in Biology from the University of North Carolina and his Ph.D. in Cell and Molecular Biology from UT Southwestern in 2007. In 2008 he was awarded the Sara and Frank McKnight junior faculty position at UT Southwestern Medical Center.  During this time his lab focused on answering a long-standing question in cancer biology regarding the cellular function of cancer-testis antigen (CTAs) proteins. In 2011 he was appointed Assistant Professor in the Departments of Physiology, Pharmacology, and Biochemistry at UT Southwestern Medical Center.

Ryan Potts

Executive Director and Head of Induced Proximity Platform
Amgen

Ryan Potts

Executive Director and Head of Induced Proximity Platform
Amgen

Ryan Potts, Ph.D. obtained his B.S. in Biology from the University of North Carolina and his Ph.D. in Cell and Molecular Biology from UT Southwestern in 2007. In 2008 he was awarded the Sara and Frank McKnight junior faculty position at UT Southwestern Medical Center.  During this time his lab focused on answering a long-standing question in cancer biology regarding the cellular function of cancer-testis antigen (CTAs) proteins. In 2011 he was appointed Assistant Professor in the Departments of Physiology, Pharmacology, and Biochemistry at UT Southwestern Medical Center. His lab’s work defined a function for the enigmatic MAGE gene family in protein regulation through ubiquitination. In 2016 his lab moved to St. Jude Children’s Research Hospital where he was an Associate Member in the Department of Cell and Molecular Biology. There his lab continued to work on CTAs, with a focus on elucidating the biochemical, cellular, physiological and pathological functions of the MAGE gene family. In 2020 he moved to Amgen, Inc. in Thousand Oaks, California to build a new department called the Induced Proximity Platform (IPP) that is focused on drugging the “undruggable”.

 

Raj Lehal

Chief Scientific Officer
Cellestia Biotech AG

Raj Lehal

Chief Scientific Officer
Cellestia Biotech AG

Raj Lehal

Chief Scientific Officer
Cellestia Biotech AG
 

Amit Choudhary

Assistant Professor
Harvard Medical School

Amit grew up in a farmer’s family in India and like the other kids “in the hood”, his early career aspirations included joining the army or becoming a cricketer. Amit’s pre-doctoral studies at the Indian Institute of Science‒Bangalore (IISc) involved the total synthesis of natural products and protein folding studies. He was ranked among top 5 students nationwide in the entrance exams of IITs and IISc. In 2006, he moved to Univ.

Amit Choudhary

Assistant Professor
Harvard Medical School

Amit Choudhary

Assistant Professor
Harvard Medical School

Amit grew up in a farmer’s family in India and like the other kids “in the hood”, his early career aspirations included joining the army or becoming a cricketer. Amit’s pre-doctoral studies at the Indian Institute of Science‒Bangalore (IISc) involved the total synthesis of natural products and protein folding studies. He was ranked among top 5 students nationwide in the entrance exams of IITs and IISc. In 2006, he moved to Univ. of Wisconsin‒Madison to pursue his graduate studies with Prof. Ron Raines. Amit’s doctoral thesis describes the discovery of a force (termed n→π* interactions) that is akin to the hydrogen bond in its quantum mechanical origin and widespread prevalence in biomolecules.

Amit got interested in infectious disease and diabetes on observing a rampant prevalence of tuberculosis-triggered diabetes in many Indian families, including his own. In 2011, Amit was elected as a Harvard Junior Fellow and hosted by Prof. Stuart Schreiber at the Broad Institute. Here, he decided to shift his research focus from quantum mechanical interactions to infectious disease and diabetes. In 2015, he was appointed as an Assistant Professor of Medicine at Harvard Medical School and he also holds appointments at the Brigham & Women’s Hospital and the Broad Institute. The efforts of Amit’s group have been recognized by Burroughs Wellcome Fund’s Career Award at the Scientific InterfaceNIH Director’s Transformative Research AwardDARPA’s SAFE GENES awardVilcek Prize for Creative Promise, and Juvenile Diabetes Research Foundation’s Innovation Award.

 

Woody Sherman

Chief Computational Scientist
Roivant Sciences

Woody Sherman

Chief Computational Scientist
Roivant Sciences

Woody Sherman

Chief Computational Scientist
Roivant Sciences
 

Jim Wells

Professor
UCSF

Jim Wells

Professor
UCSF

Jim Wells

Professor
UCSF
 

Toren Finkel

CSO
Generian Pharmaceuticals

Toren Finkel

CSO
Generian Pharmaceuticals

Toren Finkel

CSO
Generian Pharmaceuticals
 

Ellen Vieux

Senior Scientist
C4 Theraputics

Ellen Vieux

Senior Scientist
C4 Theraputics

Ellen Vieux

Senior Scientist
C4 Theraputics
 

Pan Zheng Qiang

Professor
Icahn School of Medicine at Mount Sinai

Pan Zheng Qiang

Professor
Icahn School of Medicine at Mount Sinai

Pan Zheng Qiang

Professor
Icahn School of Medicine at Mount Sinai
 

Yue Xiong

CSO
Cullgen

Yue Xiong

CSO
Cullgen

Yue Xiong

CSO
Cullgen
 

Green Ahn

PhD Candidate
Stanford University

Green Ahn

PhD Candidate
Stanford University

Green Ahn

PhD Candidate
Stanford University
 

Yun Ge

Junior Principal Investigator
Harvard University

Yun Ge

Junior Principal Investigator
Harvard University

Yun Ge

Junior Principal Investigator
Harvard University
 

Dengfeng Dou

VP
HitGen

Dengfeng Dou

VP
HitGen

Dengfeng Dou

VP
HitGen
 

Haojing Rong

Vice President of Preclinical Development
Kymera

Haojing Rong

Vice President of Preclinical Development
Kymera

Haojing Rong

Vice President of Preclinical Development
Kymera
 

Igor Stagljar

Professor in Departments of Biochemistry and Molecular Genetics
Donnelly Centre, University of Toronto

Igor Stagljar

Professor in Departments of Biochemistry and Molecular Genetics
Donnelly Centre, University of Toronto

Igor Stagljar

Professor in Departments of Biochemistry and Molecular Genetics
Donnelly Centre, University of Toronto
 

Jared Gollob

MD Chief Medical Officer
Kymera Therapeutics

Jared Gollob

MD Chief Medical Officer
Kymera Therapeutics

Jared Gollob

MD Chief Medical Officer
Kymera Therapeutics
 

Kumar Suresh

Senior Director of R&D
Progenra

Kumar Suresh

Senior Director of R&D
Progenra

Kumar Suresh

Senior Director of R&D
Progenra
 

Nicolas Bery

Senior Postdoctoral Scientist
Cancer Research Centre of Toulouse

Nicolas Bery

Senior Postdoctoral Scientist
Cancer Research Centre of Toulouse

Nicolas Bery

Senior Postdoctoral Scientist
Cancer Research Centre of Toulouse
 

Vincenzo D'Angiolella

Associate Professor
Oxford Institute for Radiation Oncology

Vincenzo D'Angiolella

Associate Professor
Oxford Institute for Radiation Oncology

Vincenzo D'Angiolella

Associate Professor
Oxford Institute for Radiation Oncology
 

Charu Chaudhry Senior

Principal Scientist
The Janssen Pharmaceutical Companies of Johnson & Johnson

Charu Chaudhry Senior

Principal Scientist
The Janssen Pharmaceutical Companies of Johnson & Johnson

Charu Chaudhry Senior

Principal Scientist
The Janssen Pharmaceutical Companies of Johnson & Johnson
 

Alex Federation

Co-Founder & Chief Executive Officer
Talus Bio

Alex Federation

Co-Founder & Chief Executive Officer
Talus Bio

Alex Federation

Co-Founder & Chief Executive Officer
Talus Bio
 

Kusal Samarasinghe

Postdoctoral Associate
Yale

Kusal Samarasinghe

Postdoctoral Associate
Yale

Kusal Samarasinghe

Postdoctoral Associate
Yale
 

Ian Pike

Chief Scientific Office
Proteome Sciences

Ian Pike is the Chief Scientific Officer at Proteome Sciences and has 30 years’ experience working in the diagnostics and biotechnology sectors. Having gained a PhD in Medical Microbiology, he joined Welcome Diagnostics as a research group leader and spent 8 years working on new diagnostic assays, particularly for hepatitis. In December 1999, he joined the Technology Transfer Office of the UK Medical Research Council with responsibility for patents and commercialization of a wide portfolio of technologies related to the biomedical sector.

Ian Pike

Chief Scientific Office
Proteome Sciences

Ian Pike

Chief Scientific Office
Proteome Sciences

Ian Pike is the Chief Scientific Officer at Proteome Sciences and has 30 years’ experience working in the diagnostics and biotechnology sectors. Having gained a PhD in Medical Microbiology, he joined Welcome Diagnostics as a research group leader and spent 8 years working on new diagnostic assays, particularly for hepatitis. In December 1999, he joined the Technology Transfer Office of the UK Medical Research Council with responsibility for patents and commercialization of a wide portfolio of technologies related to the biomedical sector. Ian also worked for Cancer Research Ventures managing intellectual property and performing business development activities in Europe and the USA. Since joining Proteome Sciences in 2002 he has held a number of roles covering intellectual property management, business development, operational management and is now focused on leading the Company’s scientific strategy to offer clients a flexible, high quality service.

Advisory Board

Author:

Adam Gilbert

Executive Director, Head of Design and Synthesis Sciences
Pfizer

My group supports several important medchem platforms for Pfizer: protein degradation, DNA-encoded library chemistry, large and small-scale compound purification and phenotypic screening deconvolution.  Scientists in my group specialize in design and synthetic medicinal chemistry, computational chemistry, purification science as well as molecular property analysis.

Adam Gilbert

Executive Director, Head of Design and Synthesis Sciences
Pfizer

My group supports several important medchem platforms for Pfizer: protein degradation, DNA-encoded library chemistry, large and small-scale compound purification and phenotypic screening deconvolution.  Scientists in my group specialize in design and synthetic medicinal chemistry, computational chemistry, purification science as well as molecular property analysis.

Author:

John Castle

CDS
Monte Rosa Therapeutics

John Castle

CDS
Monte Rosa Therapeutics

Author:

Matthew Calabrese

Senior Director and head of Structural and Molecular Science
Pfizer

Matthew Calabrese

Senior Director and head of Structural and Molecular Science
Pfizer

Author:

Ryan Potts

Executive Director and Head of Induced Proximity Platform
Amgen

Ryan Potts, Ph.D. obtained his B.S. in Biology from the University of North Carolina and his Ph.D. in Cell and Molecular Biology from UT Southwestern in 2007. In 2008 he was awarded the Sara and Frank McKnight junior faculty position at UT Southwestern Medical Center.  During this time his lab focused on answering a long-standing question in cancer biology regarding the cellular function of cancer-testis antigen (CTAs) proteins. In 2011 he was appointed Assistant Professor in the Departments of Physiology, Pharmacology, and Biochemistry at UT Southwestern Medical Center. His lab’s work defined a function for the enigmatic MAGE gene family in protein regulation through ubiquitination. In 2016 his lab moved to St. Jude Children’s Research Hospital where he was an Associate Member in the Department of Cell and Molecular Biology. There his lab continued to work on CTAs, with a focus on elucidating the biochemical, cellular, physiological and pathological functions of the MAGE gene family. In 2020 he moved to Amgen, Inc. in Thousand Oaks, California to build a new department called the Induced Proximity Platform (IPP) that is focused on drugging the “undruggable”.

Ryan Potts

Executive Director and Head of Induced Proximity Platform
Amgen

Ryan Potts, Ph.D. obtained his B.S. in Biology from the University of North Carolina and his Ph.D. in Cell and Molecular Biology from UT Southwestern in 2007. In 2008 he was awarded the Sara and Frank McKnight junior faculty position at UT Southwestern Medical Center.  During this time his lab focused on answering a long-standing question in cancer biology regarding the cellular function of cancer-testis antigen (CTAs) proteins. In 2011 he was appointed Assistant Professor in the Departments of Physiology, Pharmacology, and Biochemistry at UT Southwestern Medical Center. His lab’s work defined a function for the enigmatic MAGE gene family in protein regulation through ubiquitination. In 2016 his lab moved to St. Jude Children’s Research Hospital where he was an Associate Member in the Department of Cell and Molecular Biology. There his lab continued to work on CTAs, with a focus on elucidating the biochemical, cellular, physiological and pathological functions of the MAGE gene family. In 2020 he moved to Amgen, Inc. in Thousand Oaks, California to build a new department called the Induced Proximity Platform (IPP) that is focused on drugging the “undruggable”.

Author:

Shaomeng Wang

Professor of Internal Medicine, Pharmacology and Medicinal Chemistry
University of Michigan

I have been working on the discovery and development of novel small-molecules therapeutics for more than 20 years. One area of my research has been focused on targeting protein-protein interactions which regulate apoptosis, including the PPIs between the anti-death Bcl-2 and pro-death Bcl-2 members, the MDM2-p53 PPI, and the PPI of IAP proteins with Smac. My research in targeting apoptosis has resulted in the discovery and advancement of 8 compounds into Phase I/II clinical development targeting Bcl-2/Bcl-xL, MDM2 and IAP proteins. In more recent years, I have expanded my research program to target a number of PPIs, which regulate epigenetics, including histone readers, writers and erasers, and have advanced several classes of compounds into advanced preclinical development. To accomplish our goals of discovering highly optimized compounds suitable for clinical development and rapidly advancing them into clinical development, I have established extensive collaborations with basic scientists, translational scientists and clinical investigators at UMCCC and in other institutions. I have co-founded five UM start-up companies to help us to bring our drugs into clinical development and marketplace. I have published 300+ peer-reviewed papers and an inventor of 50+ issued US patents and hundreds of international patents. I was elected as Fellow of the National Academy of Inventors in 2014 and as Fellow of the American Association for the Advancement of Science (AAAS) in 2019, was induced into Hall of Fame of the Division of Medicinal Chemistry of American Chemical Society in 2020. I was the 2014 University of Michigan Distinguished Innovator.

Shaomeng Wang

Professor of Internal Medicine, Pharmacology and Medicinal Chemistry
University of Michigan

I have been working on the discovery and development of novel small-molecules therapeutics for more than 20 years. One area of my research has been focused on targeting protein-protein interactions which regulate apoptosis, including the PPIs between the anti-death Bcl-2 and pro-death Bcl-2 members, the MDM2-p53 PPI, and the PPI of IAP proteins with Smac. My research in targeting apoptosis has resulted in the discovery and advancement of 8 compounds into Phase I/II clinical development targeting Bcl-2/Bcl-xL, MDM2 and IAP proteins. In more recent years, I have expanded my research program to target a number of PPIs, which regulate epigenetics, including histone readers, writers and erasers, and have advanced several classes of compounds into advanced preclinical development. To accomplish our goals of discovering highly optimized compounds suitable for clinical development and rapidly advancing them into clinical development, I have established extensive collaborations with basic scientists, translational scientists and clinical investigators at UMCCC and in other institutions. I have co-founded five UM start-up companies to help us to bring our drugs into clinical development and marketplace. I have published 300+ peer-reviewed papers and an inventor of 50+ issued US patents and hundreds of international patents. I was elected as Fellow of the National Academy of Inventors in 2014 and as Fellow of the American Association for the Advancement of Science (AAAS) in 2019, was induced into Hall of Fame of the Division of Medicinal Chemistry of American Chemical Society in 2020. I was the 2014 University of Michigan Distinguished Innovator.

3rd
Event in the series
100+
Delegates
40+
Speakers
1
Must-Attend Industry Event

view the 2022 Agenda

Why join us at Protein Degradation & Targeting Undruggables?

  1. Get the latest clinical and pre-clinical developments in targeted protein degraders to optimise the clinical landscape
  2. Uncover emerging modalities and new therapeutic targets to develop your commercial pipeline
  3. Discover emerging strategies to induce TPD outside of PROTACs and molecular glues
  4. Hear case studies in PROTAC-mediated protein degradation to develop an understanding of bioavailability and PK to inform your R&D projects
  5. Understand how leading pharma use proteomics strategies, PKPD mechanistic modeling, and AI to assess protein degrader modality 

Download the agenda

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:
Preparing registration...

Past attendees

Who will be there

30%
Pharma
30%
Biotech
20%
Academics
20%
Service Providers / Vendors

Pharma

Biotech

Academics

Service Providers / Vendors

Become a Partner

Kisaco Research provides the platform where industry executives can network, learn and meet potential industry partners.

Far from the typical ‘meet-and-greet’ experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand.

Your partnership with Kisaco Research will offer you a strategic approach that is an extension and enhancement of your own marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets.

Find out more by calling us at +44 (0)20 3696 2920 or email [email protected]

Event Partner

Exhibitor

Media Partners

Venue

Hilton Boston Back Bay 40 Dalton Street Boston, MA 02115

Book your room HERE.

Resources

Download Resource

Contact Us

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.